In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.
August 2026 | Volume 19 | No 3
To sign up for our newsletter or print publications, please enter your contact information below.
